STAT+: 在上海“科学城”,中国崛起中的生物科技公司向全球推介自身
STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
上海“科学城”内,包括 Abbisko 在内的多家中国生物科技公司向全球展示其药物研发效率。Abbisko 联合创始人朱晨表示,该公司一项授权给 Merck KGaA 的药物临床试验在 11 个月内完成,其速度之快甚至促使 Merck 高管询问能否培训其员工。
![]()
By Jason Mast
Oct. 1, 2026
General Assignment Reporter
SHANGHAI — The biotech executives appeared triumphant.
It was a balmy, overcast Sunday here in the glimmer-and-glass “Science City” district, and the four leaders were on stage at the ballroom level of the five-star Hilton, joking about how much faster, cheaper, and more efficient drug development was here in China than anywhere else — certainly than the United States. (And God help Europe.)
Zhui Chen, co-founder of the now $6 billion Shanghai-based biotech Abbisko, recalled running a trial on a drug licensed to the German pharma Merck KGaA. Abbisko’s trial finished in 11 months, so quickly that Merck executives asked if Abbisko could train their staff.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com